Atypical osteomalacia after 2 year etidronate intermittent cyclic administration in osteoporosis.
A 68-year-old postmenopausal woman with osteoporosis received intermittent cyclic etidronate therapy (400 mg/day). No concomitant diseases were noted. A baseline transiliac bone biopsy showed a high bone turnover without impairment due to mineralization. After 2 years of treatment, she had increased osteoid volume, and mineralization lag time corresponded to a variant form of osteomalacia called atypical osteomalacia. No clinical consequence was observed. This is the first case report of such a mineralization defect due to 2 year intermittent cyclic etidronate therapy.
Thomas
T
T
Laboratoire de Biologia du Tissu Osseux, Université de Saint Etienne, France.
Lafage
M H
MH
Alexandre
C
C
D000368:Aged; D015519:Bone Density; D004334:Drug Administration Schedule; D012968:Etidronic Acid / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D010018:Osteomalacia / Q000139:chemically induced* / Q000378:metabolism; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*
D012968:Etidronic Acid